Bio-Techne Corp (TECH) Stock Price, Quote & News

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors,...

Industry: Biotechnology

Sector: Healthcare

Phone: 612 379 8854

Fax: 612 656 4400

Website: www.bio-techne.com

Address:

614 McKinley Place N.E., Minneapolis, United States

Fizz26 Jun. 26 at 5:47 PM

$DJIA $TECH ! Go long

0 · Reply

ITZONLINEMONIE Jun. 25 at 11:34 PM

$TECH really disappointed techne

0 · Reply

DonCorleone77 Jun. 24 at 11:04 AM

$TECH Bio-Techne, USP collaborate to develop monoclonal antibody and gene therapy Bio-Techne announced a distribution agreement with the U.S. Pharmacopeia, or USP, that enables the company to sell USP monoclonal antibody and recombinant adeno-associated virus, or AAV, reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide. Maintaining consistent mAb quality is vital for their efficacy. Both USP mAbs and AAV reference standards provide stringent materials that can be used with Bio-Techne's analytical instruments, such as the MauriceFlex system.

0 · Reply

JarvisFlow Jun. 16 at 12:30 PM

Baird has updated their rating for Bio-Techne ( $TECH ) to Outperform with a price target of 88.

0 · Reply

BallaclavaBoys Jun. 12 at 6:03 PM

$TECH Over bought

0 · Reply

ITZONLINEMONIE Jun. 12 at 5:47 PM

$TECH lets get up and out techne

0 · Reply

ZacksResearch May. 29 at 4:06 PM

$TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today? Click here to learn more: https://www.zacks.com/stock/news/2478718/is-bio-techne-stock-the-right-pick-for-your-portfolio-now?cid=sm-stocktwits-2-2478718-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478718_TEASER

0 · Reply

ZacksResearch May. 29 at 1:12 PM

$TECH down 38.1% over the past year — what's dragging it down? 📉 Despite high single-digit growth in GMP reagents and strategic acquisitions, Bio-Techne faces macroeconomic headwinds, including rising costs and global tariffs, affecting its margins. Understand the risks before investing in TECH 👉 https://www.zacks.com/commentary/2478718/is-bio-techne-stock-the-right-pick-for-your-portfolio-now?cid=sm-stocktwits-2-2478718-body&ADID=SYND_STOCKTWITS_TWEET_2_2478718_BODY

0 · Reply

stuntman9883 May. 20 at 1:48 PM

$TECH https://youtu.be/6bliafouSEA?si=nnlho3ueDdXrON5o good financials

0 · Reply

if_at_first May. 14 at 7:13 PM

$TECH From 54 to 48 in three days. An 11% drop ... why?

0 · Reply

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

Jun 10, 2025, 7:00 AM EDT - 17 days ago

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

May 29, 2025, 7:00 AM EDT - 4 weeks ago

Bio-Techne to Present at Investor Conferences

May 14, 2025, 7:00 AM EDT - 6 weeks ago

ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)

May 12, 2025, 7:00 AM EDT - 6 weeks ago

Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

May 8, 2025, 9:30 AM EDT - 7 weeks ago

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing

May 8, 2025, 7:00 AM EDT - 7 weeks ago

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

May 7, 2025, 10:38 AM EDT - 7 weeks ago

Bio-Techne Corporation (TECH) Q3 2025 Earnings Call Transcript

May 7, 2025, 8:18 AM EDT - 7 weeks ago

Bio-Techne exceeds profit expectations, announces new share buyback plan

May 7, 2025, 6:30 AM EDT - 7 weeks ago

BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

May 7, 2025, 6:30 AM EDT - 7 weeks ago

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

May 6, 2025, 7:00 AM EDT - 7 weeks ago

ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.

Apr 29, 2025, 7:00 AM EDT - 2 months ago

ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy

Apr 24, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection

Apr 23, 2025, 7:00 AM EDT - 2 months ago

Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 2, 2025, 7:00 AM EDT - 3 months ago

Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument

Mar 26, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany

Mar 24, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting

Mar 10, 2025, 7:00 AM EDT - 3 months ago

Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System

Mar 3, 2025, 7:00 AM EST - 4 months ago

Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes

Feb 27, 2025, 9:00 AM EST - 4 months ago

Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain

Feb 20, 2025, 7:00 AM EST - 4 months ago

Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology

Feb 18, 2025, 7:00 AM EST - 4 months ago

Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System

Feb 5, 2025, 2:24 PM EST - 5 months ago

Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript

Feb 5, 2025, 6:30 AM EST - 5 months ago

Bio-Techne Declares Dividend

Feb 5, 2025, 6:30 AM EST - 5 months ago

Bio-Techne Releases Second Quarter Fiscal 2025 Results

Feb 4, 2025, 7:00 AM EST - 5 months ago

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

Jan 21, 2025, 7:00 AM EST - 5 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio

Jan 21, 2025, 7:00 AM EST - 5 months ago

Bio-Techne to Host Conference Call on February 5, 2025, to Announce Second Quarter Fiscal 2025 Financial Results

Jan 10, 2025, 7:00 AM EST - 6 months ago

Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine

Jan 8, 2025, 7:00 AM EST - 6 months ago

BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025

Jan 8, 2025, 7:00 AM EST - 6 months ago

ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics

Jan 7, 2025, 7:00 AM EST - 6 months ago

BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC

Dec 20, 2024, 7:00 AM EST - 6 months ago

BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Dec 19, 2024, 7:00 AM EST - 6 months ago

BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT

Dec 18, 2024, 7:00 AM EST - 6 months ago

ScaleReady awards a G-Rex® Grant to Moonlight Bio

Dec 12, 2024, 7:00 AM EST - 7 months ago

BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY

Dec 10, 2024, 7:00 AM EST - 7 months ago

BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY

Nov 27, 2024, 7:00 AM EST - 7 months ago

BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE

Nov 25, 2024, 9:02 AM EST - 7 months ago

Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne

Nov 22, 2024, 9:00 AM EST - 7 months ago

OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements

Nov 20, 2024, 7:00 AM EST - 7 months ago

BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES

Nov 18, 2024, 7:00 AM EST - 7 months ago

BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH

Nov 14, 2024, 7:00 AM EST - 8 months ago

BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO

Nov 11, 2024, 5:47 PM EST - 8 months ago

UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS

Nov 11, 2024, 7:00 AM EST - 8 months ago

BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS

Nov 8, 2024, 7:00 AM EST - 8 months ago

BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES

Nov 7, 2024, 7:00 AM EST - 8 months ago

ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy

Nov 6, 2024, 7:00 AM EST - 8 months ago

BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING

Nov 5, 2024, 7:00 AM EST - 8 months ago

LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH

Fizz26 Jun. 26 at 5:47 PM

$DJIA $TECH ! Go long

0 · Reply

ITZONLINEMONIE Jun. 25 at 11:34 PM

$TECH really disappointed techne

0 · Reply

DonCorleone77 Jun. 24 at 11:04 AM

0 · Reply

JarvisFlow Jun. 16 at 12:30 PM

Baird has updated their rating for Bio-Techne ( $TECH ) to Outperform with a price target of 88.

0 · Reply

BallaclavaBoys Jun. 12 at 6:03 PM

$TECH Over bought

0 · Reply

ITZONLINEMONIE Jun. 12 at 5:47 PM

$TECH lets get up and out techne

0 · Reply

ZacksResearch May. 29 at 4:06 PM

0 · Reply

ZacksResearch May. 29 at 1:12 PM

0 · Reply

stuntman9883 May. 20 at 1:48 PM

$TECH https://youtu.be/6bliafouSEA?si=nnlho3ueDdXrON5o good financials

0 · Reply

if_at_first May. 14 at 7:13 PM

$TECH From 54 to 48 in three days. An 11% drop ... why?

0 · Reply

Estimize May. 14 at 10:00 AM

Wall St is expecting 0.51 EPS for $TECH Q4 [Reporting 08/12 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co

0 · Reply

Thestocktraderhubzee May. 12 at 11:20 AM

$TECH Bio-Techne To Showcase Latest Spatial Biology And Cell And Gene Therapy Workflow Solutions At ASGCT 2025 Meeting

0 · Reply

JarvisFlow May. 9 at 10:30 PM

UBS updates rating for Bio-Techne ( $TECH ) to Buy, target set at 95 → 70.

0 · Reply

d_risk May. 9 at 4:36 PM

$TECH - Bio-Techne Corp Common Stock - 10Q - Updated Risk Factors No material changes overall, but new risks flagged on global market uncertainties, tariffs, sanctions, and trade actions affecting costs, supply chains, pricing, and demand, with ongoing U.S.-China tariff tensions and potential trade policy shifts highlighted. #GlobalMarketRisks #US-ChinaTensions #TradePolicyUncertainty #SupplyChainDisruption #TariffsImpact 🟢 Added 🟠 Removed https://d-risk.ai/TECH/10-Q/2025-05-08

0 · Reply

JarvisFlow May. 8 at 5:13 PM

RBC Capital updates rating for Bio-Techne ( $TECH ) to Sector Perform, target set at 72 → 63.

0 · Reply

JarvisFlow May. 8 at 1:59 PM

Benchmark has adjusted their stance on Bio-Techne ( $TECH ), setting the rating to Buy with a target price of 95 → 75.

0 · Reply

lighting_ball May. 7 at 7:48 PM

$TECH got some calls, let’s see where this goes!

0 · Reply

UnionRef May. 7 at 3:07 PM

$TECH beat earnings...announce buyback...and still goes down. Short interest is almost nothing. So what is going on with this one?

0 · Reply

pillz May. 7 at 2:58 PM

$TECH members of congress are buying that sit on biotech committee. Buy $5K worth and hold.

0 · Reply

OpenOutcrier May. 7 at 12:40 PM

$TECH (+4.8% pre) Bio-Techne (NASDAQ:TECH) Posts Q1 Sales In Line With Estimates, Stock Soars https://finance.yahoo.com/news/bio-techne-nasdaq-tech-posts-104302187.html

0 · Reply

Armonica423 May. 6 at 1:07 PM

$TECH CYDY

0 · Reply

Market Cap	8.28B
Revenue (ttm)	1.16B
Net Income (ttm)	168.11M
EPS (ttm)	N/A
PE Ratio	30.34
Forward PE	31.18
Profit Margin	14.50%
Debt to Equity Ratio	0.16

Volume	2,486,300
Avg Vol	2,418,192
Day's Range	N/A - N/A
Shares Out	156.77M
Stochastic %K	69%
Beta	1.38
Analysts	Strong Sell
Price Target	$66.17